Please wait...


Generic Name: dolutegravir and rilpivirine
Brand Names: Juluca
Juluca (dolutegravir and rilpivirine) is used to treat HIV-1 infection. Includes Juluca side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Juluca

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Juluca contains a combination of dolutegravir and rilpivirine. Dolutegravir and rilpivirine are antiviral medicines that prevents human immunodeficiency virus (HIV) from multiplying in your body. Juluca is used to treat HIV, the virus that can cause the acquired immunodeficiency syndrome (AIDS). Juluca is not a cure for HIV or AIDS. Juluca is for use only in people who have been successfully treated with other antiviral medications for at least 6 months. Taking Juluca during the first trimester of pregnancy may cause birth defects. Use effective birth control to prevent pregnancy while you are using dolutegravir. Learn more

Juluca Side Effects

Juluca Side Effects

Note: This document contains side effect information about dolutegravir / rilpivirine. Some of the dosage forms listed on this page may not apply to the brand name Juluca.

For the Consumer

Applies to dolutegravir/rilpivirine: oral tablet

Along with its needed effects, dolutegravir / rilpivirine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dolutegravir / rilpivirine:

Less common

  • Abnormal dreams
  • anxiety
  • cloudy or bloody urine
  • dark urine
  • decreased frequency or amount of urine
  • depressed mood
  • gaseous stomach pain
  • general feeling of tiredness or weakness
  • increased blood pressure
  • increased thirst
  • indigestion
  • light-colored stools
  • loss of appetite
  • lower back or side pain
  • nausea
  • recurrent fever
  • severe nausea or vomiting
  • stomach fullness or pain
  • suicidal thoughts, attempt, or behavior
  • swelling of the face, fingers, feet, or lower legs
  • trouble sleeping
  • troubled breathing
  • unusual tiredness or weakness
  • upper right abdominal pain
  • vomiting
  • weight gain
  • yellow eyes or skin

Incidence not known

  • Decreased appetite
  • difficulty swallowing
  • fast heartbeat
  • fever
  • headache
  • skin itching, rash, or redness
  • stomach tenderness
  • stomach pain, continuing
  • swelling of the face, throat, or tongue

Some side effects of dolutegravir / rilpivirine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Bloated feeling
  • diarrhea
  • dizziness
  • excess air or gas in the stomach or bowels
  • feeling of fullness
  • muscle pain
  • passing gas
  • sleepiness or unusual drowsiness

Incidence not known

  • Difficulty in moving
  • joint pain or swelling
  • muscle ache, cramp, or stiffness

For Healthcare Professionals

Applies to dolutegravir / rilpivirine: oral tablet


In clinical trials, dolutegravir plus rilpivirine was discontinued due to side effects in 4% of patients. The most common side effects leading to discontinuation were psychiatric disorders.

Nervous system

Very common (10% or more): Headache, dizziness

Common (1% to 10%): Somnolence


-Very common (10% or more): Headache

-Common (1% to 10%): Dizziness


-Common (1% to 10%): Headache, dizziness

-Uncommon (0.1% to 1%): Somnolence


Very common (10% or more): Nausea, increased pancreatic amylase, diarrhea

Common (1% to 10%): Abdominal pain, vomiting, elevated lipase, gastroenteritis, dyspepsia, upper abdominal pain, constipation, flatulence, abdominal distention, abdominal discomfort, dry mouth


-Very common (10% or more): Nausea, diarrhea

-Common (1% to 10%): Abdominal pain, vomiting, flatulence, upper abdominal pain, abdominal discomfort


-Common (1% to 10%): Abdominal pain, nausea, vomiting

-Uncommon (0.1% to 1%): Abdominal discomfort

Grade 2 and grade 3 to 4 elevations in lipase were reported in 5% and 2% of patients, respectively.


Very common (10% or more): Increased fasted total cholesterol, increased fasted low-density lipoprotein cholesterol

Common (1% to 10%): Fatigue, asthenia, syphilis, increased fasted triglycerides


-Common (1% to 10%): Fatigue

-Postmarketing reports: Increased weight


-Common (1% to 10%): Fatigue


Very common (10% or more): Insomnia

Common (1% to 10%): Depression, abnormal dreams, sleep disorders, depressed mood, anxiety

Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt

Frequency not reported: Depressive disorders (including depressed mood, depression, suicidal ideation/attempt/behavior/completion)


-Common (1% to 10%): Insomnia, abnormal dreams, depression, anxiety

-Uncommon (0.1% to 1%): Suicidal ideation, suicide attempt


-Common (1% to 10%): Depression, insomnia, abnormal dreams, sleep disorders

-Uncommon (0.1% to 1%): Depressed mood

Suicidal ideation or suicide attempt was reported, mainly in patients with history of depression or psychiatric illness.

Depressive disorders occurred primarily in patients with history of depression or other psychiatric illness.


Very common (10% or more): Increased transaminases (elevated ALT and/or AST)

Common (1% to 10%): Elevated ALT, elevated total bilirubin

Uncommon (0.1% to 1%): Hepatitis

Frequency not reported: Cholecystitis, cholelithiasis, elevated AST, hepatic toxicity, elevated serum liver biochemistries, liver chemistry elevations


-Uncommon (0.1% to 1%): Hepatitis

-Frequency not reported: Elevations in transaminases (consistent with immune reconstitution syndrome or hepatitis B reactivation)

-Postmarketing reports: Acute liver failure, hepatotoxicity


-Common (1% to 10%): Increased transaminases

Grade 2 and grade 3 to 4 elevations in ALT were reported in 2% and less than 1% of patients, respectively. Grade 2 elevations in total bilirubin were reported in 2% of patients. Grade 2 and grade 3 to 4 elevations in AST were each reported in less than 1% of patients.

The incidence of liver chemistry elevations was higher in patients coinfected with hepatitis C than in those who were not coinfected.

In some patients using dolutegravir-containing regimens, elevations in transaminases were consistent with immune reconstitution syndrome or hepatitis B reactivation, especially when antihepatitis therapy was stopped.


Common (1% to 10%): Hyperglycemia, decreased appetite


-Common (1% to 10%): Decreased appetite

Grade 2 and grade 3 to 4 hyperglycemia were reported in 4% and less than 1% of patients, respectively.


Common (1% to 10%): Elevated creatine phosphokinase, decreased bone mineral density (BMD), arthralgia, back pain, pain in extremity

Uncommon (0.1% to 1%): Fractures (excluding fingers and toes), myalgia

Frequency not reported: Myositis, increased BMD, asymptomatic elevated creatine phosphokinase


-Postmarketing reports: Arthralgia, myalgia

BMD increased (total hip and lumbar spine) from baseline to week 48 in patients who switched from a tenofovir disoproxil fumarate (DF)-containing antiretroviral regimen to dolutegravir plus rilpivirine compared with patients who continued using a tenofovir DF-containing antiretroviral regimen. BMD declines of at least 5% at the lumbar spine were reported in 2% of patients using this drug and 5% of patients who continued using a tenofovir DF-containing antiretroviral regimen. The long-term clinical relevance of such BMD changes has not been established.

Grade 2 and grade 3 to 4 elevations in creatine phosphokinase were reported in less than 1% and 1% of patients, respectively.

Elevated creatine phosphokinase was reported, primarily associated with exercise.


Common (1% to 10%): Rash, pruritus


-Common (1% to 10%): Rash, pruritus


-Common (1% to 10%): Rash

-Postmarketing reports: Severe skin and hypersensitivity reactions (including drug reaction with eosinophilia and systemic symptoms [DRESS])

Grade 2 to 3 therapy-related rashes were reported in 3% of patients during phase 3 trials of rilpivirine.


Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, bronchitis, sinusitis, influenza


Common (1% to 10%): Decreased WBC count, decreased hemoglobin, decreased platelet count


Uncommon (0.1% to 1%): Hypersensitivity


-Uncommon (0.1% to 1%): Hypersensitivity reactions (characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury)


Frequency not reported: Membranous glomerulonephritis, mesangioproliferative glomerulonephritis, nephrolithiasis, renal impairment, increased serum creatinine


-Postmarketing reports: Nephrotic syndrome

Both components of this drug have increased serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 48 weeks. A mean change from baseline of 0.093 mg/dL (range: -0.3 to 0.58 mg/dL) or 8.22 mcmol/L (range: -26.5 to 51.2 mcmol/L) was reported after 48 weeks of therapy; these changes were not considered clinically significant.


Frequency not reported: Immune reconstitution syndrome


-Uncommon (0.1% to 1%): Immune reconstitution syndrome


In the pooled phase 3 trials, at week 96, there was an overall mean change from baseline in basal cortisol of -0.69 mcg/dL in the rilpivirine group, and of -0.02 mcg/dL in the efavirenz group.

In the rilpivirine group, 43 of 588 patients with normal 250 mcg ACTH stimulation test at baseline developed abnormal 250 mcg ACTH stimulation test (peak cortisol level less than 18.1 mcg/dL) during the trial versus 18 of 561 patients in the efavirenz group. Abnormal 250 mcg ACTH stimulation test at week 96 was seen in 14 of the 43 rilpivirine patients and 9 of the 18 efavirenz patients. Overall, there were no serious side effects, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency. Clinical significance of abnormal 250 mcg ACTH stimulation tests in the rilpivirine group has not been established.


-Frequency not reported: Decreased basal cortisol, abnormal 250 mcg adrenocorticotropic hormone (ACTH) stimulation test, adrenal insufficiency

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Juluca